Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences

Related GILD
These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market
Gilead Sciences Bucks Trend In Biotech Short Interest
Gilead, Price Controls' Supporting Role in the Midterms (Fox Business)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD), but lowered its price target from $95.00 to $48.00.

Deutsche Bank noted, “We are updating our TP and EPS estimates for Gilead's recent 2:1 stock split. Our new TP is $48 & our pre-split TP was $95. Our new 4Q12, FY 2012 and 2013 non-GAAP EPS estimates are $.51, $1.98, and $2.35 respectively. New 4Q12 fully diluted share count is 1582 with average share count of 1568 for FY 2012. We have made no changes to our revenue projections or expenses. Our thesis remains unchanged on HCV & HIV.”

Gilead Sciences closed on Tuesday at $39.90.

Latest Ratings for GILD

DateFirmActionFromTo
Dec 2014Morgan StanleyMaintainsEqual-weight
Dec 2014JP MorganMaintainsOverweight
Nov 2014NomuraMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters